Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients

FMD vaccination of pastoral sheep and goat to be extended pan India: Animal Husbandry Minister

Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland

This project is supported by the Irish Government through IDA Ireland

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer

Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years

Biostar Pharma gets FDA clearance of the IND application for a Phase 2 study of Utidelone Injection

Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux

Increasing public awareness on World Zoonoses Day

India boasts the largest livestock population, with 536 million livestock and 851 million poultry

Eugia SEZ’s injectable facility gets EIR from USFDA

The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated

Pfizer reports positive results from Echelon-3 study

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone

Suven to acquire a majority stake in CDMO player ‘Sapala Organics’

Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies

AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer

PICCOLO trial met its primary endpoint of objective response rate (ORR)